Loading company…
Microbion develops microbial bioenergetic inhibitors, led by Pravibismane, for chronic and antibiotic-resistant infections.
Microbion's lead product, Pravibismane, disrupts microbial metabolism and targets biofilms in chronic infections, with two Phase 2 studies for diabetic foot ulcer infections and orthopedic-device-related infections. Founded in 2000 and headquartered in Bozeman, US, the company has raised a total of USD 2.1 mn, most recently in June 2022 from investors including CUBRC and the Medical Technology Enterprise Consortium.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in